COVID‐19 and diabetes

Ma, Rong; Holt, Richard

doi:10.1111/dme.14300

Cited by 151 publications

(151 citation statements)

References 15 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…[3,4] Diabetic individuals have a greater risk of respiratory infections due to compromised immune system, especially the innate immunity. [5,37] Even transient hyperglycaemia may temporarily affect innate immune responses to infection. [38] It was hypothesized that ACE2 may be the key pathfinder of COVID-19 severity in diabetic individuals.…”

Section: Discussionmentioning

confidence: 99%

“…[38] It was hypothesized that ACE2 may be the key pathfinder of COVID-19 severity in diabetic individuals. [5] ACE2 is a type 1 integral membrane glycoprotein expressed in the epithelial cells of cardiovascular, pulmonary, renal, brain and intestinal tissue, it acts by breaking down angiotensin II into angiotensin 1-7. [37,39,40] This enzyme acts by counteracting the inflammatory actions of angiotensin II, lowering the concentration of pro-inflammatory cytokine interleukin (IL)-6, increasing the anti-inflammatory, and increasing the antioxidant action of angiotensin 1-7, escalating the levels of surfactant protein D and promoting vasodilation.…”

Section: Discussionmentioning

confidence: 99%

“…[39] Viral surface spike (S) protein of COVID-19 binds to ACE2 after spike protein activation by transmembrane protease serine 2 (TMPRSS2). [40] Routine use of ACEI and ARB as a medication for chronic conditions upregulates ACE2 expression, [5,37] thereby facilitating entry of SARS-CoV-2 into the pneumocytes and consequently cause severe and fatal infection. [42] Among other diabetic medications, the use of liraglutide and pioglitazone have also been found to be related with increased ACE2 regulation in animal studies.…”

Section: Discussionmentioning

confidence: 99%

“…[3,4] It was postulated that the angiotensin converting enzyme 2 (ACE2) may be the plausible explanation of this association. [5] In this study, we aimed to perform a systematic review and meta-analysis in order to investigate the association between DM and poor outcome in patients with pneumonia. Our hypothesis is that DM is associated with poor outcome in patients with COVID-19 pneumonia.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression

Huang

Lim

Pranata

2020

Diabetes & Metabolic Syndrome: Clinical Research & Revi

823

747

View full text Add to dashboard Cite

Background and AimsDiabetes Mellitus (DM) is chronic conditions with devastating multi-systemic complication and may be associated with severe form of Coronavirus Disease 2019 . We conducted a systematic review and meta-analysis in order to investigate the association between DM and poor outcome in patients with COVID-19 pneumonia. MethodsSystematic literature search was performed from several electronic databases on subjects that assess DM and outcome in COVID-19 pneumonia. The outcome of interest was composite poor outcome, including mortality, severe COVID-19, acute respiratory distress syndrome (ARDS), need for intensive care unit (ICU) care, and disease progression. ResultsThere were a total of 6452 patients from 30 studies. Meta-analysis showed that DM was associated with composite poor outcome (RR 2.38 [1.88,3.03], p<0.001; I 2 : 62%) and its subgroup which comprised of mortality (RR 2.12 [1.44, 3.11], p<0.001; I 2 : 72%), severe COVID-19 (RR 2.45 [1.79, 3.35], p<0.001; I 2 : 45%), ARDS (RR 4.64 [1.86,11.58], p=0.001; I 2 : 9%), and disease progression (RR 3.31 [1.08, 10.14], p=0.04; I 2 : 0%). Meta-regression showed that the association with composite poor outcome was influenced by age (p=0.003) and hypertension (p<0.001). Subgroup analysis showed that the association was weaker in studies with median age ≥55 years-old (RR 1.92) compared to <55 years-old (RR 3.48), and in prevalence of hypertension ≥25% (RR 1.93) compared to <25% (RR 3.06). Subgroup analysis on median age <55 years-old and prevalence of hypertension <25% showed strong association (RR 3.33) ConclusionDM was associated with mortality, severe COVID-19, ARDS, and disease progression in patients with COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression

Huang

Lim

Pranata

2020

Diabetes & Metabolic Syndrome: Clinical Research & Revi

823

747

View full text Add to dashboard Cite

show abstract

“…Diabetes mellitus is a frequent co-morbidity and a cause of worse prognosis in COVID-19 patients [12,[144][145][146][147][148]. Indeed, evaluating pneumonia cases of unknown causes reported in Wuhan and in patients with history of exposure to Huanan seafood market before Jan 1, 2020, 20% had diabetes [85].…”

Section: Diabetes and Covid-19mentioning

confidence: 99%

Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence

Sardu

Gambardella

Morelli

et al. 2020

JCM

469

436

View full text Add to dashboard Cite

The symptoms most commonly reported by patients affected by coronavirus disease (COVID-19) include cough, fever, and shortness of breath. However, other major events usually observed in COVID-19 patients (e.g., high blood pressure, arterial and venous thromboembolism, kidney disease, neurologic disorders, and diabetes mellitus) indicate that the virus is targeting the endothelium, one of the largest organs in the human body. Herein, we report a systematic and comprehensive evaluation of both clinical and preclinical evidence supporting the hypothesis that the endothelium is a key target organ in COVID-19, providing a mechanistic rationale behind its systemic manifestations.

show abstract

Coronavirus disease 2019 (COVID‐19) and obesity. Impact of obesity and its main comorbidities in the evolution of the disease

Cornejo‐Pareja

Pérez

Fernández‐García

et al. 2020

Euro Eating Disorders Rev

View full text Add to dashboard Cite

The COVID-19 pandemic is posing a great challenge worldwide. Its rapid progression has caused thousands of deaths worldwide. Although multiple aspects remain to be clarified, some risk factors associated with a worse prognosis have been identified. These include obesity and some of its main complications, such as diabetes and high blood pressure. Furthermore, although the possible long-term complications and psychological effects that may appear in survivors of COVID-19 are not well known yet, there is a concern that those complications may be greater in obese patients. In this manuscript, we review some of the data published so far and the main points that remain to be elucidated are emphasized.

show abstract

COVID‐19 and diabetes

Cited by 151 publications

References 15 publications

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression

Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence

Coronavirus disease 2019 (COVID‐19) and obesity. Impact of obesity and its main comorbidities in the evolution of the disease

Contact Info

Product

Resources

About